Advertisement

The Epidermal Growth Factor Receptor in Breast Cancer

  • Stephen B. Fox
  • Adrian L. Harris
Article

Abstract

The epidermal growth factor receptor (EGFR)3 is a 170 kD transmembrane tyrosine kinase activated by several ligands. It is required for normal mammary development and lactation and is aberrantly expressed in approximately 40% of breast carcinomas, particularly those with a poor prognostic phenotype. Since EGF receptor levels are elevated in a high proportion of many tumor types its potential as a therapy target is being investigated using the EGF receptor to target toxins, as well as drugs that interfere with signaling and anti-receptor antibodies. These approaches are likely to be most effective when used in the adjuvant situation in combination with chemotherapy.

Prognostic phenotype embryogenesis adipose tissue sialoadenectomy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    B. Gusterson, G. Cowley, J. A. Smith, and B. Ozanne (1984). Cellular localization of human epidermal growth factor receptor. Cell Biol. Int. Rep. 8:649–658.Google Scholar
  2. 2.
    F. X. Real, W. J. Rettig, P. G. Chesa, M. R. Melamed, L. J. Old, and J. Mendelsohn (1986). Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res. 46:4726–4731.Google Scholar
  3. 3.
    A. L. Harris, (1989). Epidermal growth factor receptor in human breast cancer. Recent Results Cancer Res. 113:70–77.Google Scholar
  4. 4.
    S. Okamoto and T. Oka (1984). Evidence for physiological function of epidermal growth factor: pregestational sialoadenectomy of mice decreases milk production and increases off-spring mortality during lactation period. Proc. Natl. Acad. Sci. U.S.A. 81:6059–6063.Google Scholar
  5. 5.
    K. J. Fowler, F. Walker, W. Alexander, M. L. Hibbs, E. C. Nice, R. M. Bohmer, G. B. Mann, C. Thumwood, R. Maglitto, J. A. Danks, R. Chetty, A. Burgess, and A. Dunn (1995). A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. Proc. Natl. Acad. Sci. U.S.A. 92:1465–1469.Google Scholar
  6. 6.
    S. Scala, T. Saeki, A. Lynch, D. Salomon, M. J. Merino, and S. E. Bates (1995). Coexpression of TGF alpha, epidermal growth factor receptor, and P-glycoprotein in normal and benign diseased breast tissues. Diagn. Mol. Pathol. 4:136–142.Google Scholar
  7. 7.
    I. Damjanov, B. Mildner, and B. Knowles (1986). Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. Lab. Invest. 55:588–592.Google Scholar
  8. 8.
    P. Moller, G. Mechtersheimer, M. Kaufmann, G. Moldenhauer, F. Momburg, T. Mattfeldt, and H. F. Otto (1989). Expression of epidermal growth factor receptor in benign and malignant primary tumors of the breast. Virchows Arch. A Pathol, Anat. Histopathol. 414:157–164.Google Scholar
  9. 9.
    Y. Tsutsumi, S. P. Naber, R. A. DeLellis, H. J. Wolfe, P. J. Marks, S. J. McKenzie, and S. Yin (1990). neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues. Hum. Pathol. 21:750–758.Google Scholar
  10. 10.
    R. Dittadi, P. M. Donisi, A. Brazzale, L. Cappellozza, G. Bruscagnin, and M. Gion (1993). Epidermal growth factor receptor in breast cancer. Comparison with non malignant breast tissue. Br. J. Cancer. 67:7–9.Google Scholar
  11. 11.
    M. T. Travers, L. P. Barrett, U. Berger, Y. A. Luqmani, J. C. Gazet, T. J. Powles, and R. C. Coombes (1988). Growth factor expression in normal, benign, and malignant breast tissue Br. Med. J. Clin. Res. Ed. 296:1621–1624.Google Scholar
  12. 12.
    Y. Mizukami, A. Nonomura, M. Noguchi, T. Taniya, N. Koyasaki, Y. Saito, T. Hashimoto, F. Matsubara, and N. Yanihara (1991). Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas. Anticancer Res. 11:xx–xx.Google Scholar
  13. 13.
    T. Wada, M. Yasutomi, K. Yamada, M. Kunikata, H. Higashiyama, P. Shrestha, and M. Mori (1991). Immunohistochemical expression of epidermal growth factor receptor in benign and malignant lesions of the breast. Acta Histochem. Cytochem. 24:449–455.Google Scholar
  14. 14.
    M. Zelada-Hedman, G. Werer, P. Collins, M. Backdahl, I. Perez, S. Franco, J. Jimenez, J. Cruz, M. Torroella, and M. Nordenskjold (1994). High expression of the EGFR in fibroadenomas compared to breast carcinomas. Anticancer Res. 14:1679–1688.Google Scholar
  15. 15.
    J. R. Sainsbury, G. Sherbet, J. R. Farndon, and A. L. Harris (1985). Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet 1:364–366.Google Scholar
  16. 16.
    F. Battaglia, G. Scambia, S. Rossi, P. B. Panici, R. Bellantone, G. Polizzi, P. Querzoli, R. Negrini, S. Iacobelli, F. Crucitti, and et al. (1980). Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement Eur. J. Cancer Clin. Oncol. 24:1685–1690. Published erratum appears in Eur. J. Cancer Clin. Oncol. 25(3):577.Google Scholar
  17. 17.
    F. Pekonen, S. Partanen, T. Makinen, and E. M. Rutanen (1988). Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res. 48:1343–1347.Google Scholar
  18. 18.
    T. Mori, T. Morimoto, K. Komaki, and Y. Monden (1991). Comparison of estrogen receptor and epidermal growth factor receptor content of primary and involved nodes in human breast cancer. Cancer 68:532–537.Google Scholar
  19. 19.
    A. Rosenthal, P. B. Lindquist, T. S. Bringman, D. V. Goeddel, and R. Derynck (1986). Expression in rat fibroblasts of a human transforming growth factor-alpha cDNA results in transformation. Cell 46:301–309.Google Scholar
  20. 20.
    P. P. DiFiore, J. H. Pierce, T. P. Fleming, R. Hazan, A. Ullrich, C. R. King, J. Schlessinger, and S. A. Aaronson (1987). Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51:1063–1070.Google Scholar
  21. 21.
    M. C. Maa, T. H. Leu, D. J. McCarley, R. C. Schatzman, and S. J. Parsons (1995). Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc. Natl. Acad. Sci. U.S.A. 92:6981–6985.Google Scholar
  22. 22.
    E. Sandgren, N. Luetteke, R. Palmiter, R. Brinster, and D. Lee (1990). Overexpression of TGFa in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61:1121–1135.Google Scholar
  23. 23.
    P. G. Koenders, D. Faverly, L. V. Beex, E. D. Bruggink, C. B. Kienhuis, and T. J. Benraad (1992). Epidermal growth factor receptors in human breast cancer: a plea for standardization of assay methodology. Eur. J. Cancer 28:693–697.Google Scholar
  24. 24.
    A. Rallet, M. J. Faroux, S. Theobald, L. M. Caquot, C. Pourny, M. Pluot, and J. C. Jardillier (1994). Epidermal growth factor receptors in breast cancer: comparison of radioligand and immunocytochemical assays. Anticancer Res. 14:1417–1421.Google Scholar
  25. 25.
    H. Iwase, S. Kobayashi, Y. Itoh, T. Kuzushima, H. Yamashita, H. Iwata, A. Naito, T. Yamashita, K. Itoh, and A. Masaoka (1993). Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer. Breast Cancer Res. Treat. 28:215–221.Google Scholar
  26. 26.
    J. C. Newby, R. P. A'Hern, R. D. Leek, I. E. Smith, A. L. Harris, and M. Dowsett (1995). Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer. Br. J. Cancer 71:1237–1242.Google Scholar
  27. 27.
    S. A. Chrysogelos, R. I. Yarden, A. H. Lauber, and J. M. Murphy (1994). Mechanisms of EGF receptor regulation in breast cancer cells. Breast Cancer Res. Treat. 31:227–236.Google Scholar
  28. 28.
    E. Petrangeli, C. Lubrano, L. Ravenna, A. Vacca, M. R. Cardillo, L. Salvatori, F. Sciarra, L. Frati, and A. Gulino (1995). Gene methylation of estrogen and epidermal growth-factor receptors in neoplastic and perineoplastic breast tissues. Br. J. Cancer 72:973–975.Google Scholar
  29. 29.
    E. Petrangeli, C. Lubrano, L. Ravenna, A. Vacca, M. R. Cardillo, L. Salvatori, F. Sciarra, L. Frati, and A. Gulino (1995). Gene methylation of oestrogen and epidermal growth factor receptors in neoplastic and perineoplastic breast tissues. Br. J. Cancer 72:973–975.Google Scholar
  30. 30.
    S. LeJeune, R. Leek, E. Horak, G. Plowman, M. Greenall, and A. L. Harris (1993). Amphiregulin, epidermal growth factor receptor and oestrogen receptor expression in human primary breast cancer. Cancer Res. 53:3597–3602.Google Scholar
  31. 31.
    L. C. Groenen, E. C. Nice, and A. W. Burgess (1994). Structure-function-relationships for the EGF/tgf-alpha family of mitogens. Growth Factors 11:235–257.Google Scholar
  32. 32.
    H. Toyoda, T. Komurasaki, D. Uchida, Y. Takayama, T. Isobe, T. Okuyama, and K. Hanada (1995). Epiregulin—a novel epidermal growth-factor with mitogenic activity for rat primary hepatocytes. J. Biol. Chem. 270:7495–7500.Google Scholar
  33. 33.
    R. Lupu, M. Cardillo, L. Harris, M. Hijazi, and K. Rosenberg (1995). Interaction between erbb-receptors and heregulin in breast-cancer tumor progression and drug-resistance. Semin Cancer Biol. 6:135–145.Google Scholar
  34. 34.
    T. Saeki, D. S. Salomon, G. R. Johnson, W. J. Gullick, K. Mandai, K. Yamagami, S. Moriwaki, M. Tanada, S. Takashima, and E. Tahara (1995). Association of epidermal growth factor-related peptides and type-1 receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn. J. Clin. Oncol. 25:240–249.Google Scholar
  35. 35.
    H. I. Scher, A. Sarkis, V. Reuter, D. Cohen, G. Netto, D. Petrylak, P. Lianes, Z. Fuks, J. Mendelsohn, and C. Cordoncardo (1995). Changing pattern of expression of the epidermal growth-factor receptor and transforming growth-factor-alpha in the progression of prostatic neoplasms. Clin. Cancer Res. 1:545–550.Google Scholar
  36. 36.
    N. Normanno, N. Kim, D. Z. Wen, K. Smith, A. L. Harris, G. Plowman, G. Colletta, F. Ciardiello, and D. S. Salomon (1995). Expression of messenger-RNA for amphiregulin, heregulin and cripto-1, 3 new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Res. Treat. 35:293–297.Google Scholar
  37. 37.
    S. Fitzpatrick, J. Brightwell, J. Wittliff, G. Barrows, and G. Schultz (1984). Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res. 44:3448–3453.Google Scholar
  38. 38.
    P. Bolufer, F. Miralles, A. Rodriguez, C. Vazquez, A. Lluch, C. J. Garcia, and T. Olmos (1990). Epidermal growth factor receptor in human breast cancer: correlation with cytosolic and nuclear ER receptors and with biological and histological tumor characteristics. Eur. J. Cancer 26:283–290.Google Scholar
  39. 39.
    C. Charpin, B. Devictor, P. Bonnier, L. Andrac, M. N. Lavaut, C. Allasia, and L. Piana (1993). Epidermal growth factor receptor in breast cancer: correlation of quantitative immunocytochemical assays to prognostic factors. Breast Cancer Res. Treat. 25:203–210.Google Scholar
  40. 40.
    J. G. Klijn, M. P. Look, H. Portengen, F. J. Alexieva, P. W. van, and J. A. Foekens (1994). The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res. Treat. 29:73–83.Google Scholar
  41. 41.
    M. J. Railo, K. V. Smitten, and F. Pekonen (1994). The prognostic value of epidermal growth factor receptor (EGFR) in breast cancer patients. Results of a follow-up study on 149 patients. Acta Oncol. 33:13–17.Google Scholar
  42. 42.
    F. Spyratos, P. M. Martin, K. Hacene, C. Andrieu, S. Romain, J. L. Floiras, and H. Magdelenat (1994). Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay—a retrospective study. Breast Cancer Res. Treat. 29:85–95.Google Scholar
  43. 43.
    M. Toi, T. Tominaga, A. Osaki, and T. Toge (1994). Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study. Breast Cancer Res. Treat. 29:51–58.Google Scholar
  44. 44.
    R. Wyss, D. Fabbro, R. Regazzi, C. Borner, A. Takahashi, and U. Eppenberger (1987). Phorbol ester and epidermal growth factor receptors in human breast cancer. Anticancer Res. 7:721–727.Google Scholar
  45. 45.
    S. B. Fox, K. Smith, J. Hollyer, M. Greenall, D. Hastrich, and A. L. Harris (1994). The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat. 29:41–49.Google Scholar
  46. 46.
    V. Cappelletti, M. Brivio, P. G. Miodini, D. Coradini, and G. Di Fronzo (1988). Simultaneous estimation of epidermal growth factor receptors and steroid receptors in a series of 136 resectable primary breast tumors. Tumor Biol. 9:200–211.Google Scholar
  47. 47.
    P. J. Hainsworth, M. A. Henderson, R. G. Stillwell, and R. C. Bennett (1991). Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer. Eur. J. Surg. Oncol. 17:9–15.Google Scholar
  48. 48.
    M. Bilous, J. Milliken, and J. M. Mathijs (1992). Immunocytochemistry and in situ hybridization of epidermal growth factor receptor and relation to prognostic factors in breast cancer. Eur. J. Cancer.Google Scholar
  49. 49.
    G. Gasparini, P. Boracchi, P. Bevilacqua, M. Mezzetti, F. Pozza, and N. Weidner (1994). A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma. Breast Cancer Res. Treat. 29:59–71.Google Scholar
  50. 50.
    J. C. Delarue, S. Friedman, H. Mouriesse, L. F. May, G. H. Sancho, and G. Contesso (1988). Epidermal growth factor receptor in human breast cancers: correlation with estrogen and progesterone receptors. Breast Cancer Res. Treat. 11:173–178.Google Scholar
  51. 51.
    M. Bolla, M. Chedin, C. Souvignet, J. Marron, C. Arnould, and E. Chambaz (1990). Estimation of epidermal growth factor receptor in 177 breast cancers: correlation with prognostic factors. Breast Cancer Res. Treat. 16:97–102.Google Scholar
  52. 52.
    J. R. Sainsbury, A. J. Malcolm, D. R. Appleton, J. R. Farndon, and A. L. Harris (1985). Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J. Clin. Pathol. 38:1225–1228.Google Scholar
  53. 53.
    P. G. Koenders, L. V. Beex, M. A. Geurts, J. J. Heuvel, C. B. Kienhuis, and T. J. Benraad (1991). Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res. 51:4544–4548.Google Scholar
  54. 54.
    A. K. Sharma, K. Horgan, J. A. Douglas, R. McClelland, J. Gee, and R. Nicholson (1994). Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br. J. Cancer. 69:1032–1037.Google Scholar
  55. 55.
    C. Doglioni, T. A. Dei, L. Laurino, C. Chiarelli, M. Barbareschi, and G. Viale (1994). The prevalence of BCL-2 immuno-reactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch. 424:47–51.Google Scholar
  56. 56.
    R. D. Leek, L. Kaklamanis, F. Pezzella, K. C. Gatter, and A. L. Harris (1994). BCL-2 in normal human breast and carcinoma, association with oestrogen receptor positive, epidermal growth factor receptor negative tumors and in situ cancer. Br. J. Cancer 69:135–139.Google Scholar
  57. 57.
    G. Cattoretti, F. Rilke, S. Andreola, L. D'Amato, and D. Delia (1988). P53 expression in breast cancer. Int. J. Cancer 41:178–183.Google Scholar
  58. 58.
    D. N. Poller, C. E. Hutchings, M. Galea, J. A. Bell, R. A. Nicholson, C. W. Elston, R. W. Blamey, and I. O. Ellis (1992). p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br. J. Cancer 66:583–588.Google Scholar
  59. 59.
    D. J. Dabbs (1995). Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-B-2. Mod. Pathol. 8:637–642.Google Scholar
  60. 60.
    F. Wrba, A. Reiner, E. Ritzinger, J. H. Holzner, and G. Reiner (1988). Expression of epidermal growth factor receptors (EGFR) on breast carcinomas in relation to growth fractions, estrogen receptor status and morphological criteria. An immunohistochemical study. Pathol. Res. Pract. 183:25–29.Google Scholar
  61. 61.
    R. I. Nicholson, R. A. McClelland, J. M. Gee, D. L. Manning, P. Cannon, J. F. Robertson, I. O. Ellis, and R. W. Blamey (1994). Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res. Treat. 29:117–125.Google Scholar
  62. 62.
    G. K. Needham, S. Nicholson, B. Angus, J. R. Farndon, and A. L. Harris (1988). Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors. Cancer Res. 48:6603–6607.Google Scholar
  63. 63.
    G. G. McIntosh, J. J. Anderson, I. Milton, M. Steward, A. H. Parr, M. D. Thomas, J. A. Henry, B. Angus, T. W. Lennard, and C. H. Horne (1995). Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11:885–891.Google Scholar
  64. 64.
    J. Folkman (1990). What is the evidence that tumors are angiogenesis dependent. J. Natl. Cancer Inst. 82:4–6.Google Scholar
  65. 65.
    G. Rice and M. Bevilacqua (1988). An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science 246:1303–1306.Google Scholar
  66. 66.
    A. B. Schreiber, M. E. Winkler, and R. Derynck (1986). Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 232:1250–1253.Google Scholar
  67. 67.
    C. Goldman, J. Kim, W.-L. Wong, V. King, T. Brock, and G. Gillespie (1993). Epidermal growth factor stimulates vascular endothelial cell growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell 4:121–133.Google Scholar
  68. 68.
    S. B. Fox, R. D. Leek, K. Smith, J. Hollyer, M. Greenall, and A. L. Harris (1994). Tumor angiogenesis in node-negative breast carcinomas—relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res. Treat. 29:109–116.Google Scholar
  69. 69.
    N. Weidner and G. Gasparini (1994). Determination of epidermal growth factor receptor provides additional prognostic information to measuring tumor angiogenesis in breast carcinoma patients. Breast Cancer Res. Treat. 29:97–107.Google Scholar
  70. 70.
    E. Horak, R. Leek, N. Klenk, S. LeJeune, K. Smith, N. Stuart, M. Greenall, K. Stepniewska, and A. L. Harris (1992). Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as an indicator of node metastasis and survival in breast cancer. Lancet 340:1120–1124.Google Scholar
  71. 71.
    N. Weidner, J. Folkman, F. Pozza, P. Bevilacqua, E. Allred, D. Moore, S. Meli, and G. Gasparini (1992). Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J. Natl. Cancer Inst. 84:1875–1887.Google Scholar
  72. 72.
    J. R. Sainsbury, J. R. Farndon, G. K. Needham, A. J. Malcolm, and A. L. Harris (1987). Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1:1398–1402.Google Scholar
  73. 73.
    S. Nicholson, J. Richard, C. Sainsbury, P. Halcrow, P. Kelly, B. Angus, C. Wright, J. Henry, J. R. Farndon, and A. L. Harris (1991). Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br. J. Cancer 63:146–150.Google Scholar
  74. 74.
    J. G. Klijn, P. M. Berns, P. I. Schmitz, and J. A. Foekens (1992). The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrinol. Rev. 13:3–17.Google Scholar
  75. 75.
    J. G. Klijn, P. M. Berns, P. I. Schmitz, and J. A. Foekens (1993). Epidermal growth factor receptor (EGF-R) in clinical breast cancer: update 1993. Endocrinol. Rev. Monographs, 1:171–174.Google Scholar
  76. 76.
    M. A. Rios, A. Macias, R. Perez, A. Lage, and L. Skoog (1988). Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res. 8:173–176.Google Scholar
  77. 77.
    S. Costa, H. Stamm, A. Almendral, H. Ludwig, R. Wyss, D. Fabbro, A. Ernst, A. Takahashi, and U. Eppennberger (1988). Predictive value of EGF receptor in breast cancer. Lancet 2:1258.Google Scholar
  78. 78.
    M. Grimaux, S. Romain, Y. Remvikos, P. M. Martin, and H. Magdelenat (1989). Prognostic value of epidermal growth factor receptor in node-positive breast cancer. Breast Cancer Res. Treat. 14:77–90.Google Scholar
  79. 79.
    J. A. Foekens, H. Portengen, P. W. van, A. M. Trapman, J. C. Reubi, F. J. Alexieva, and J. G. Klijn (1989). Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res. Google Scholar
  80. 80.
    S. Lewis, A. Locker, J. H. Todd, J. A. Bell, R. Nicholson, C. W. Elston, R. W. Blamey, and I. O. Ellis (1990). Expression of epidermal growth factor receptor in breast carcinoma. J. Clin. Pathol. 43:385–389.Google Scholar
  81. 81.
    F. Spyratos, J. C. Delarue, C. Andrieu, R. Lidereau, M. H. Champeme, K. Hacene, and M. Brunet (1990). Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res. Treat. 17:83–89.Google Scholar
  82. 82.
    M. Toi, A. Osaki, H. Yamada, and T. Toge (1991). Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur. J. Cancer 27:977–980.Google Scholar
  83. 83.
    R. Hawkins, E. Killen, I. Whittle, W. Jack, U. Chetty, and R. Prescott (1991). Epidermal growth factor receptors in intracranial and breast tumors: their clinical significance. Br. J. Cancer 63:553–560.Google Scholar
  84. 84.
    P. Shrestha, K. Yamada, T. Wada, S. Maeda, M. Watatani, M. Yasutomi, H. Takagi, and M. Mori (1992). Proliferating cell nuclear antigen in breast lesions: correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer. Virchows Arch A Pathol. Anat. Histopathol. 421:193–202.Google Scholar
  85. 85.
    G. Gasparini, P. Bevilacqua, F. Pozza, S. Meli, P. Boracchi, E. Marubini, and J. Sainsbury (1992). Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br. J. Cancer 66:970–976.Google Scholar
  86. 86.
    A. Osaki, M. Toi, H. Yamada, H. Kawami, K. Kuroi, and T. Toge (1992). Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am. J. Surg. 164:323–326.Google Scholar
  87. 87.
    M. Bolla, M. Chedin, M. Colonna, J. Marron, P. B. Rostaing, and E. Chambaz (1992). Prognostic value of epidermal growth factor receptor in a series of 303 breast cancers. Eur. J. Cancer 28A:1052–1054.Google Scholar
  88. 88.
    P. Murray, P. Barrett-Lee, M. Travers, Y. Luqmani, T. Powles, and R. Coombes (1993). The prognostic significance of transforming growth factors in human breast cancer. Br. J. Cancer 67:1408–1412.Google Scholar
  89. 89.
    P. G. Koenders, L. V. Beex, C. B. Kienhuis, P. W. Kloppenborg, and T. J. Benraad (1993). Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study. Breast Cancer Res. Treat. 25:21–27.Google Scholar
  90. 90.
    M. Noguchi, Y. Mizukami, K. Kinoshita, M. Earashi, M. Thomas, and I. Miyazaki (1994). The prognostic significance of epidermal growth factor receptor expression in breast cancer. Surg. Today. 24:889–894.Google Scholar
  91. 91.
    G. Gasparini, F. Pozza, and A. Harris (1993). Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J. Natl. Cancer Inst. 85:1206–1219.Google Scholar
  92. 92.
    H. S. Earp, T.L. Dawson, X. Li, and H. Yu (1995). Heterodimerization and functional interaction between EGF receptor family members—a new signaling paradigm with implications for breast-cancer research. Breast Cancer Res. Treat. 35:115–132.Google Scholar
  93. 93.
    C. Wright, B. Angus, S. Nicholson, J. R. C. Sainsbury, J. Cairns, W. J. Gullick, P. Kelly, A. L. Harris, and C. H. W. Horne (1989). Expression of c-erbB-2 oncoprotein: a prognostic indicator in breast cancer. Cancer Res. 49:2087–2090.Google Scholar
  94. 94.
    E.B.C.T.C. Group (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1–15; 71–85.Google Scholar
  95. 95.
    S. Nicholson, P. Halcrow, J. R. C. Sainsbury, B. Angus, P. Chambers, J. R. Farndon, and A. L. Harris (1988). Epidermal growth factor receptor status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br. J. Cancer 58:810–814.Google Scholar
  96. 96.
    S. Nicholson, J. R. C. Sainsbury, P. Halcrow, P. Chambers, J. R. Farndon, and A. L. Harris, (1989). Epidermal growth factor receptor expression is associated with lack of response to endocrine therapy in patients with recurrent breast cancer. Lancet 1:182–185.Google Scholar
  97. 97.
    J. G. Klijn, E. M. Berns, and J. A. Foekens (1993). Prognostic factors and response to therapy in breast cancer. Cancer Surv. 18:165–198.Google Scholar
  98. 98.
    S. G. Archer, A. Eliopoulos, D. Spandidos, D. Barnes, I. O. Ellis, R. W. Blamey, R. I. Nicholson, and J. F. Robertson (1995). Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br. J. Cancer 72:1259–1266.Google Scholar
  99. 99.
    C. Wright, J. Cairns, B. J. Cantwell, A. R. Cattan, A. G. Hall, A. L. Harris, and C. H. W. Horne (1992). Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Brit. J. Cancer 65:271–274.Google Scholar
  100. 100.
    C. Wright, S. Nicholson, B. Angus, J. R. C. Sainsbury, J. Farndon, J. Cairns, A. L. Harris, and C. H. W. Horne, (1992). Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Brit. J. Cancer 65:118–121.Google Scholar
  101. 101.
    N. I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn (1995). Biological efficacy of a chimeric antibody to the epidermal growth-factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1:1311–1318.Google Scholar
  102. 102.
    E. Tosi, O. Valota, D. R. M. Negri, E. Adobati, A. Mazzoni, R. Meazza, S. Ferrini, M. I. Colnaghi, and S. Canevari (1995). Antitumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal-antibody and its f(ab')(2) fragment against high-EGFR-expressing and low-EGFR-expressing carcinomas in nude-mice. Int. J. Cancer 62:643–650.Google Scholar
  103. 103.
    J. Baselga and J. Mendelsohn (1994). The epidermal growth factor as a target for therapy in breast carcinoma. Breast Cancer Res. Treat. 29:127–138.Google Scholar
  104. 104.
    C. J. Wikstrand, L. P. Hale, S. K. Batra, M. L. Hill, P. A. Humphrey, S. N. Kurpad, R. E. McLendon, D. Moscatello, C. N. Pegram, and C. J. Reist (1995). Monoclonal-antibodies against EGFR viii are tumor-specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55:3140–3148.Google Scholar
  105. 105.
    A. V. Patterson, H. Zhang, A. Moghaddam, R. Bicknell, D. C. Talbot, I. J. Stratford, and A. L. Harris (1995). Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deozyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Brit. J. Cancer 72:669–675.Google Scholar
  106. 106.
    D. Fitzgerald and I. Pastan (1989). Targeted toxin therapy for the treatment of cancer. J. Natl. Cancer Inst. 81:1455–1463.Google Scholar
  107. 107.
    J. Kirk, J. Carmichael, I. J. Stratford, and A. J. Harris (1994). Selective toxicity of TGFα-PE40 to ERFR-positive cell lines: Selection protection of low EGFR-expressing cell lines by EGF. Brit. J. Cancer 69:988–994.Google Scholar
  108. 108.
    R. Kroning, J. A. Jones, D. K. Hom, C. C. Chuang, R. Sanga, G. Los, S. B. Howell, and R. D. Christen (1995). Enhancement of drug-sensitivity of human malignancies by epidermal growth-factor. Br. J. Cancer 72:615–619.Google Scholar
  109. 109.
    A. Cuarteroplaza, E. Martinez-Miralles, R. Rosell, C. Vadellnadal, M. Farre, and F. X. Real (1996). Radiolocalization of squamous lung-carcinoma with i-131-labeled epidermal growth-factor. Clin. Cancer Res. 2:13–20.Google Scholar
  110. 110.
    A. Levitzki (1990). Tyrphostins—potential antiproliferative agents and novel molecular tools. Biochem. Pharmacol. 40:913–918.Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • Stephen B. Fox
    • 1
  • Adrian L. Harris
    • 1
  1. 1.Department of Cellular ScienceUniversity of Oxford, John Radcliffe HospitalOx3 9DUUnited Kingdom

Personalised recommendations